163 related articles for article (PubMed ID: 20936106)
21. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
22. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ
Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109
[TBL] [Abstract][Full Text] [Related]
24. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
25. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E
Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
Santin AD; Bellone S; Palmieri M; Zanolini A; Ravaggi A; Siegel ER; Roman JJ; Pecorelli S; Cannon MJ
J Virol; 2008 Feb; 82(4):1968-79. PubMed ID: 18057249
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
[TBL] [Abstract][Full Text] [Related]
30. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.
Maier T; Tun-Kyi A; Tassis A; Jungius KP; Burg G; Dummer R; Nestle FO
Blood; 2003 Oct; 102(7):2338-44. PubMed ID: 12714511
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Dillman RO; Cornforth AN; Nistor GI; McClay EF; Amatruda TT; Depriest C
J Immunother Cancer; 2018 Mar; 6(1):19. PubMed ID: 29510745
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.
Barbuto JA; Ensina LF; Neves AR; Bergami-Santos P; Leite KR; Marques R; Costa F; Martins SC; Camara-Lopes LH; Buzaid AC
Cancer Immunol Immunother; 2004 Dec; 53(12):1111-8. PubMed ID: 15185011
[TBL] [Abstract][Full Text] [Related]
33. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
[TBL] [Abstract][Full Text] [Related]
34. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G
Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345
[TBL] [Abstract][Full Text] [Related]
36. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
37. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells.
Schott M; Feldkamp J; Schattenberg D; Krueger T; Dotzenrath C; Seissler J; Scherbaum WA
Eur J Endocrinol; 2000 Mar; 142(3):300-6. PubMed ID: 10700726
[TBL] [Abstract][Full Text] [Related]
38. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
Nagayama H; Sato K; Morishita M; Uchimaru K; Oyaizu N; Inazawa T; Yamasaki T; Enomoto M; Nakaoka T; Nakamura T; Maekawa T; Yamamoto A; Shimada S; Saida T; Kawakami Y; Asano S; Tani K; Takahashi TA; Yamashita N
Melanoma Res; 2003 Oct; 13(5):521-30. PubMed ID: 14512794
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.
Ribas A; Camacho LH; Lee SM; Hersh EM; Brown CK; Richards JM; Rodriguez MJ; Prieto VG; Glaspy JA; Oseguera DK; Hernandez J; Villanueva A; Chmielowski B; Mitsky P; Bercovici N; Wasserman E; Landais D; Ross MI
J Transl Med; 2010 Sep; 8():89. PubMed ID: 20875102
[TBL] [Abstract][Full Text] [Related]
40. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
Bol KF; Mensink HW; Aarntzen EH; Schreibelt G; Keunen JE; Coulie PG; de Klein A; Punt CJ; Paridaens D; Figdor CG; de Vries IJ
Am J Ophthalmol; 2014 Nov; 158(5):939-47. PubMed ID: 25038326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
